CLAIMS

1. An immunoconjugate comprising a cytotoxic agent and a human or humanized antibody or functional fragment thereof comprising an antigen-binding site that is specific for Mesothelin (SEQ ID NO:36), wherein said antibody or functional fragment thereof exhibits invariant binding of Mesothelin and, wherein the antibody binding site includes a CDR 1, CDR 2 and CDR 3 wherein:
   a) said CDR 1 consists of SEQ ID NO 3 and 12,
   b) said CDR 2 consists of SEQ ID NO 6 and 15,
   c) said CDR 3 consists of SEQ ID NO 9 and 19.
   and the cytotoxic agent consists of maytansinoid or a derivative thereof.

2. The immunoconjugate according to claim 1 wherein the antibody and the maytansinoid or a derivative thereof are linked via a SPDB linker.

3. A pharmaceutical composition comprising an immunoconjugate according to claim 1 and 2, and a pharmaceutically acceptable carrier or excipient therefore.

CLAIMS

1. An immunoconjugate comprising a cytotoxic agent and a human or humanized antibody or functional fragment thereof comprising an antigen-binding site that is specific for Mesothelin (SEQ ID NO:36), wherein said antibody or functional fragment thereof exhibits invariant binding of Mesothelin and, wherein the antibody binding site includes a CDR 1, CDR 2 and CDR 3 wherein:
   a) said CDR 1 consists of SEQ ID NO 3 and 12,
   b) said CDR 2 consists of SEQ ID NO 6 and 15,
   c) said CDR 3 consists of SEQ ID NO 9 and 19.
   and the cytotoxic agent consists of maytansinoid.

2. The immunoconjugate according to claim 1 wherein the antibody and the maytansinoid are linked via a SPDB linker.

3. A pharmaceutical composition comprising an immunoconjugate according to claim 1 and 2, and a pharmaceutically acceptable carrier or excipient therefore.